Opus Genetics (IRD) Change in Account Payables (2020 - 2026)
Opus Genetics (IRD) posted quarterly Change in Account Payables of $1.2 million for Q1 2026, up 260.86% year-over-year from $320065.6 in Q1 2025, and up 43.66% quarter-over-quarter from $804000.0 in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Change in Account Payables (2020 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Change in Account Payables for 7 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 260.86% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.9 million (up 559.66% YoY), while the FY2025 annual figure was $7000.0, down 96.82% from the prior year.
- Change in Account Payables advanced to $1.2 million in Q1 2026 per IRD's latest filing, from $804000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q4 2024 and bottomed at -$1.4 million in Q2 2024.
- Historically, Change in Account Payables has averaged $114647.1 across 5 years, with a median of $102000.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 23140.0% — and 2024, when it slumped 1501.96%.
- Opus Genetics' Change in Account Payables stood at -$390000.0 in 2022, then surged by 195.64% to $373000.0 in 2023, then surged by 312.6% to $1.5 million in 2024, then tumbled by 47.76% to $804000.0 in 2025, then soared by 43.66% to $1.2 million in 2026.
- Business Quant data shows IRD's Change in Account Payables at $1.2 million in Q1 2026, $804000.0 in Q4 2025, and $906000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -2.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.57 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 804,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -89,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Sep 30, 2023 | -545,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | -390,000.00 |
| Sep 30, 2022 | -427,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Sep 30, 2021 | 55,000.00 |